Sareum Share News (SAR)

Sareum gets approval for phase one psoriasis studies in Australia

(Sharecast News) - Biotechnology developer Sareum Holdings announced on Friday that it has been granted approval by Australia's Therapeutic Goods Administration (TGA) to conduct phase one clinical studies on SDC-1801.

Sareum receives Australian approval for psoriasis drug clinical trial

Alliance News) - Sareum Holdings PLC on Friday said its application to start a phase 1 clinical trial in Australia of its lead product, psoriasis drug SDC-1801, has been approved.

AIM WINNERS & LOSERS: Aptamer says struggling to convert pipeline

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Sareum Holdings interim loss widens as touts psoriasis candidate drug

(Alliance News) - Sareum Holdings PLC on Wednesday reported an increased half-year loss for the six months to December 31, as it continued to work on its psorasis candidate drug SDC-1801.

IN BRIEF: Sareum makes trial application for SDC-1801 in Australia

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune disease and cancer - On Wednesday, says it has begun an application to perform phase one clinical studies on SDC-1801 in Australia under the clinical trial notification scheme.

UK earnings, trading statements calendar - next 7 days

Sareum looks at options as GSK division returns cancer drug candidate

(Sharecast News) - Biotechnology developer Sareum announced on Monday that GSK subsidiary Sierra Oncology has returned clinical study reports and associated documents related to 'SRA737' to Sareum's co-development partner, the CRT Pioneer Fund.

Sareum says GSK's Sierra returns clinical study reports to CRT Pioneer

(Alliance News) - Sareum Holdings PLC on Monday said that GSK PLC subsidiary Sierra Oncology Inc has completed the return of the clinical study reports relating to SRA737 to Sarerum's co-development partner CRT Pioneer Fund LP.

TRADING UPDATES: Dev Clever to cancel shares; Tintra raises funds

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Sareum confident despite recent setbacks

(Sharecast News) - Autoimmune and cancer-focussed biotechnology company Sareum said in an update on Friday that it remained "confident" despite some recent setbacks.

AIM WINNERS & LOSERS: Time Finance jumps on strong first-half results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Sareum salutes publication of SRA737 combination trial data

Sareum Holdings PLC - Cambridge, England-based biotechnology company focused on developing kinase inhibitors for autoimmune disease & cancer - Says it is pleased by the publication of data from the Phase 1/2 trial of SRA737 as a combination treatment for advanced cancers in the medical journal, Clinical Cancer Research.

IN BRIEF: Sareum widens annual loss; considers future of SRA737

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - In the year ended June 30, pretax loss widens to GBP2.6 million from GBP1.7 million a year before. No revenue is recorded in either year, but in the previous year it brought in GBP171,000 in other operating income, with none recorded for financial 2022. Says it will discuss the future of SRA737 with partner Cancer Research Technology Pioneer Fund. Earlier this month, GSK PLC subsidiary Sierra Oncology Inc said it intends to return the rights for the SRA737 cancer treatment to CPF.

Sareum plunges as GSK subsidiary Sierra returns rights for SRA737

(Alliance News) - Sareum Holdings PLC on Wednesday after Sierra Oncology Inc, a subsidiary of GSK PLC, said it intends to return the rights for SRA737 to the CRT Pioneer Fund LP.